Thrombophilia Screening: Little Role for the JAK2V617F Mutation
- The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis. Rugged, Marco; Tosetto, Alberto; Frezzato, Maurizio; Rodeghiero, Francesco // Annals of Internal Medicine;9/16/2003, Vol. 139 Issue 6, p470
Background: The clinical relevance of mild erythrocytosis (hematocrit > 0.48 in women or > 0.51 in men) or thrombocytosis (platelet count > 400 10[SUP9] cells/L) in asymptomatic persons is uncertain. Objective: To estimate the frequency of polycythemia vera or essential thrombocythemia in...
- Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Reikvam, H; Tiu, R V // Leukemia (08876924);Apr2012, Vol. 26 Issue 4, p563
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs), which generally follow a benign and indolent clinical course. However, venous thromboses are common and constitute the main cause of morbidity and mortality. The discovery of the JAK2V617F mutation...
- Four Case Reports: Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis After lntraoperative Heparin Anticoagulation. Jackson, Mark R.; Neilson, William J.; Lary, Michael; Baay, Peter; Web, Kent; Clagett, G. Patrick // Vascular & Endovascular Surgery;Jan/Feb2006, Vol. 40 Issue 1, p67
Delayed-onset heparin-induced thrombocytopenia (HIT) is a rare and only recently described condition. The authors report 4 cases of delayed-onset HIT, each of which presented with thrombotic complications 8-18 days after receiving heparin for coronary artery bypass grafting. Delayed-onset HIT...
- First-line hydroxyurea may be effective in polycythemia vera, essential thrombocytopenia. // Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p8
The article provides information on research conducted in Barcelona, Spain which found that first-line hydroxyurea may be efficient in treating essential thrombocytopenia and polycythemia vera.
- Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. Messinezy, Maria; Pearson, T.C. // BMJ: British Medical Journal (International Edition);02/22/97, Vol. 314 Issue 7080, p587
Provides information on polycythemia, thrombocytophenia and myelofibrosis. Use of the packed cell volume as the primary indicator of polycythemia; Symptoms and signs of polycythemia; Exclusion requirements for diagnosing primary thrombocytopenia; Laboratory investigations of idiopathic...
- Cutaneous porphyria in a neonate with tyrosinaemia type 1. Vanden Eijnden, Serge; Blum, Denise; Clercx, Anne; Goyens, Philippe; De Laet, Corine; Vamos, Esther // European Journal of Pediatrics;2000, Vol. 159 Issue 7, p503
Abstract A term infant born to consanguineous parents presented at birth with hypoglycaemia, thrombocytopenia, coagulopathy and hyperbilirubinaemia associated with polycythaemia due to delayed cord clamping. Despite phototherapy and correction of polycythaemia by partial exchange transfusion,...
- Polycythaemia rubra vera and congenital deafness in monozygotic twins. Fairrie, G.; Black, A.J.; McKenzie, A.W. // British Medical Journal (Clinical Research Edition);7/18/1981, Vol. 283 Issue 6285, p192
Presents case studies on polycythaemia rubra vera and congenital deafness in monozygotic twins. Establishment of the diagnosis; Absence of association between polycythemia rubra vera and deafness; Description of primary thrombocythemia.
- Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients. Randi, M. L.; Tison, T.; Ruzzon, E.; Pacquola, E.; Girolami, A. // Annals of Hematology;Apr2003, Vol. 82 Issue 4, p214
Concomitant cases of monoclonal gammopathies with polycythemia vera (PV) and essential thrombocythemia (ET) have been described. We report our experience in a large cohort of patients with ET and PV and the occurrence of M protein in such a population. Retrospective evaluation of clinical and...
- The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. Barbui, T; Thiele, J; Carobbio, A; Vannucchi, A M; Tefferi, A // Leukemia (08876924);Apr2015, Vol. 29 Issue 4, p992
A letter to the editor is presented that discusses rate of transformation from janus kinase 2 (JAK2)-mutated essential thrombocythemia (ET) to polycythemia vera (PV) influenced by the clinico-morphological diagnosis defined by the World Health Organization (WHO).